ProMIS Neurosciences Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations


· · For the · · For the · · For the · · For the ·
· · Three Months Ended · · Three Months Ended · · Six Months Ended · · Six Months Ended ·
· · June 30, · · June 30, · · June 30, · · June 30, ·
· 2025 · 2024 · 2025 · 2024 ·
Operating expenses:
Research and development	$8,749,784	$1,625,821	$14,214,034	$3,749,599
General and administrative	1,434,877	1,087,885	3,430,723	2,640,758
Total operating expenses	10,184,661	2,713,706	17,644,757	6,390,357
Loss from operations	(10,184,661)	(2,713,706)	(17,644,757)	(6,390,357)

Other income (expense):
Change in fair value of financial instruments	—	59,087	—	44,954
Interest expense	—	—	—	(76,774)
Other income	67,632	30,962	179,825	163,432
Total other income (expense), net	67,632	90,049	179,825	131,612

Net loss	$(10,117,029)	$(2,623,657)	$(17,464,932)	$(6,258,745)

Net loss per share, basic and diluted	$(0.29)	$(0.13)	$(0.50)	$(0.32)

Weighted-average of outstanding Common Shares, basic and diluted	34,851,203	19,770,739	34,851,203	19,544,908

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.